Intrathecal Ketorolac in Patients With Intrathecal Morphine Dose Escalation

This study has been withdrawn prior to enrollment.
(Study was not initiated. No subjects were screened or enrolled.)
Sponsor:
Information provided by:
Wake Forest School of Medicine
ClinicalTrials.gov Identifier:
NCT00349401
First received: July 5, 2006
Last updated: May 12, 2009
Last verified: May 2009

July 5, 2006
May 12, 2009
December 2006
Not Provided
  • VAS pain.
  • Primary analysis will be the comparison between ketorolac and placebo groups.
Same as current
Complete list of historical versions of study NCT00349401 on ClinicalTrials.gov Archive Site
Change in oral opioid dose.
Same as current
Not Provided
Not Provided
 
Intrathecal Ketorolac in Patients With Intrathecal Morphine Dose Escalation
Intrathecal Ketorolac in Patients With Intrathecal Morphine Dose Escalation

The purpose of this study is to determine how the drug ketorolac, when given with the spinal morphine, affects pain.

This study is part of a pain center grant that focuses on how pain, especially chronic neuropathic pain, alters the response to traditional and non-traditional analgesics (pain medications).

To treat persons with chronic pain, doctors sometimes implant a permanent tube in the spinal space in the back to give pain medicines. This tube, also called a spinal pump, is used to administer pain medicine directly to the spinal space. The most commonly used medicine given through the spinal pump is morphine which works well for most people, but sometimes loses tolerance, and larger and larger doses are needed, causing many side effects.

The purpose of this study is to find out if another medicine, ketorolac, when given with morphine in the spinal space, can stop or reverse the need for larger and larger doses of morphine. In animals, ketorolac has been shown to slow the need for an increase in morphine dosage and to reduce the morphine dose, while giving good pain control.

This study will enroll 30 individuals with chronic pain below the chest, caused by nerve injury, who are receiving morphine through a spinal pump. After learning to estimate pain accurately using thermal heat testing, participants will be randomly assigned to one of two study groups. Group one will receive the active study medication, ketorolac, while group two receives an inactive control (placebo). All participants will receive morphine (administered through the spinal pump). Afterwards, participants will rate their levels of pain, and provide samples of their spinal fluid (taken from the spinal tube/pump) for study. The above procedure will be repeated over a 4-week period.

Duration of the study for participants is 4 weeks, and includes ten visits to the research center, each lasting less than one hour.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Masking: Double-Blind
Primary Purpose: Treatment
Pain
  • Drug: ketorolac
  • Drug: morphine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
30
Not Provided
Not Provided

Inclusion Criteria:

  • Implanted spinal pump for at last 9 months
  • Must be receiving and the dose must have been doubled in the past 6 months
  • Currently taking 60-200 mg morphine equivalent as oral rescue per day
  • Men and women, ages 18-70
  • Weigh no more that 250 pounds
  • Neuropathic pain

Exclusion Criteria:

  • Pregnancy
  • Unstable medical problems (heart lung, liver, kidney, or nervous system)
  • Allergy to morphine, ketorolac, or drugs which may be used to treat side effects
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00349401
P01NS041386_TRIAL3
Not Provided
Not Provided
Wake Forest School of Medicine
Not Provided
Principal Investigator: James C. Eisenach, M.D. Wake Forest School of Medicine
Principal Investigator: Richard Rauck, M.D. The Center for Clinical Research
Wake Forest School of Medicine
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP